소세포 폐암에 대한 VP-16, Cisplatin 복합화학요법치료 효과
VP-16 and Cisplatin Combination Chemotherapy in Small Cell Lung Cancer
소속 상세정보
김재석
권혁찬/배성진/노명환/정원태/김효진/강창운/김종성.
KMID : 0360319950270010077
Abstract
Forty-four Patients with small cell lung cancer were treated with chemotherapy consisting of VP-16 and cisplatin(VPP). We evaluated the efficiency and toxicity of VPP combination therapy @ES and the results obtained were as follows;
@EN 1) Among the 44 treated patients, 43 were evaluated for response to VPP chemotherapy. Complete response rate was 18.6% and partial response rate was 65.1%.
2) The median overall survival duration was 39 weeks. The median survival duration was 43 weeks in limited disease, and 36 weeks in extensive duration was 43 weeks in limited disease, and 36 weeks in extensive disease, that of responder group and
nonresponder group was 43 weeks and 14 weeks respectively.
3) The median time to progression was 31 weeks in responder.
4) The toxicities occured in the course of treatment were as follows. Gastrointestinal toxici-ties(anorexia, nausea, vomiting) (93%), alopecia(100%), mild nephrotoxicities (21.4%), and hematologic toxicities like leukopenia(36.3%) and
thrombocytopenia
(0.7%), but only one case has more than grade Ⅲleukopenia.
There results suggest that VPP combination therapy was effective in small cell lung cancer as first line chemotherapy, because its relative high response rate and mild toxicities.
키워드
원문 및 링크아웃 정보
등재저널 정보